Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3 CAR-M
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GPC3 CAR-M is a novel cell therapy utilizing chimeric antigen receptor (CAR)-modified macrophages engineered to target Glypican-3 (GPC3), a biomarker for hepatocellular carcinoma (HCC) not expressed in most adult tissues. This therapy involves transducing macrophages with an adenoviral vector delivering an anti-GPC3 CAR construct, which includes an scFv targeting GPC3 and a CD3ζ intracellular domain. These engineered GPC3 CAR-Ms exhibit antigen-specific phagocytosis and tumor cell clearance in vitro and in 3D spheroid models of HCC, alongside promoting the expression of pro-inflammatory (M1) cytokines and chemokines, indicating potent antitumor activity. The drug is being developed by Carisma Therapeutics and Moderna for the treatment of hepatocellular carcinoma.
- Other names
- anti-GPC3 CAR-Manti-GPC-3 CAR-Manti-GPC 3 CAR-MGPC3 CAR-MGPC-3 CAR-MGPC 3 CAR-MCAR-M targeting glypican-3
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on GPC3 CAR-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3 CAR-M.